(TERMINATED)CDEB025A2307: A Randomized, Open-Label Trial of the Safety and Efficacy of DEB025/Alisporivir in Combination with Pegylated Interferon-α2a and Ribavirin (peg-IFNα2a/RBV) and Boceprevir in Combination with peg-IFNα2a/RBV in African American Tre

Project: Research project

Project Details

StatusFinished
Effective start/end date10/21/11 → 6/30/14

Funding

  • Novartis Pharmaceuticals Corporation (CDEB025A2307)